Dendrimers possess the highest surface functional density of all nanomaterials, that enables them to interact with disease pathology and disease cells in a unique, unexpected way. Our group harnesses these to develop approaches for scalable, ligand-free, cell-targeted treatments for long standing challenges, including overcoming the blood-brain barrier, non-viral gene and gene-editing delivery, oral obesity treatments, intracellular antibody delivery and more.
Development of cell-targeting (ligand free) hydroxyl PAMAM and glucose dendrimers
Ligand-free hydroxyl PAMAM and glucose dendrimers selectively target reactive inflammatory cells and injured neurons, enabling precise, systemic delivery of therapeutics across the blood-brain barrier and retina with minimal off-target effects.
Glucose dendrimer platforms targeting ‘Injured Neurons’ in the context of CNS disorders and pain.
Glucose dendrimer (GD2) platforms selectively target hyperactive neurons, enabling precise, activity-dependent delivery of drugs and genes for CNS disorders, pain, and depression.
Dendrimer-antibody conjugates (DAC’s) with novel intracellular extracellular efficacy
Dendrimer-antibody conjugates combine antibody precision with dendrimer delivery, enabling novel intra- and extracellular activity for treating neurological and ophthalmic disorders.
Dendrimer-drug conjugate (DDC’s) for systemic treatment of CNS and retinal disorders.
Systemic hydroxyl dendrimers selectively target diseased brain and retinal cells without ligands, showing efficacy across 50+ models and early trials with superior safety and broad therapeutic potential.
Johns Hopkins Medicine logo
